Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

38.57 +1.19 (+3.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗
 
Via Benzinga
News headline image
Expert Ratings for Vericel ↗
 
Via Benzinga
News headline image
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Vericel Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
News headline image
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
From Vericel Corporation
Via GlobeNewswire
News headline image
Analyst Expectations for Vericel's Future ↗
 
Via Benzinga
News headline image
Analyst Ratings for Vericel ↗
 
Via Benzinga
News headline image
What's Going On With Vericel Shares Trading Higher ↗
Vericel Corp (NASDAQ: VCEL) shares are trading higher by 13.63% to $27.10 Tuesday after the company reported preliminary FY22 revenue results. What Else? 
Via Benzinga
News headline image
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
From Vericel Corporation
Via GlobeNewswire
News headline image
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
Via Benzinga
News headline image
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
From Vericel Corporation
Via GlobeNewswire
News headline image
FDA Approves MediWound's NexoBrid For Burn Treatment ↗
 
Via Benzinga
Looking Into Vericel's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
From Vericel Corporation
Via GlobeNewswire
News headline image
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
News headline image
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
From Vericel Corporation
Via GlobeNewswire
News headline image
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
From Vericel Corporation
Via GlobeNewswire
News headline image
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.